肿瘤的适应性治疗:靶向肿瘤进化

doi:10.3760/cma.j.cn371439-20191202-00038

摘要/Abstract

摘要：

肿瘤是进化的产物,靶向肿瘤进化是有希望的肿瘤治疗方法。肿瘤适应性治疗指通过选择适应和共同进化从而阻滞肿瘤进化,其方法是重构人体和肿瘤的血管、免疫、代谢、微生物群和生物钟功能,促进人体与肿瘤作为整体共同进化,从而实现“适应”和“共生”的肿瘤治疗策略。

关键词: 肿瘤, 治疗学, 克隆进化

Abstract:

Cancer develops as result of evolution and targeting cancer evolution may be a promising cancer therapeutics. Cancer adaptive therapy is defined as targeting cancer evolution through selective adaption and co-evolution. Adaptive therapy of human cancers provides new insight into the strategies for adaption and integration through reprogramming the functions of vessel, immune, metabolism, microbiota and circadian clock, and facilitating hosts and their cancers evolution as a unit.

Key words: Neoplasms, Therapeutics, Clonal evolution

张丹丹, 岳红云, 张百红. 肿瘤的适应性治疗:靶向肿瘤进化[J]. 国际肿瘤学杂志, 2020, 47(6): 368-371.

Zhang Dandan, Yue Hongyun, Zhang Baihong. Adaptive therapy of human cancers: targeting cancer evolution[J]. Journal of International Oncology, 2020, 47(6): 368-371.

参考文献 39

[1]	Baez-Ortega A, Gori K, Strakova A, et al. Somatic evolution and global expansion of an ancient transmissible cancer lineage[J]. Science, 2019, 365(6452). pii: eaau9923. DOI: 10.1126/science.aau9923. doi: 10.1126/science.aay3158 pmid: 31371598
[2]	Amirouchene-Angelozzi N, Swanton C, Bardelli A. Tumor evolution as a therapeutic target[J]. Cancer Discov, 2017. DOI: 10.1158/2159-8290.CD-17-0343. doi: 10.1158/2159-8290.CD-20-0495 pmid: 32611733
[3]	Cui R, Medeiros T, Willemsen D, et al. Relaxed selection limits lifespan by increasing mutation load[J]. Cell, 2019, 178(2):385-399.e20. DOI: 10.1016/j.cell.2019.06.004. doi: 10.1016/j.cell.2019.06.004 pmid: 31257025
[4]	Bakhoum SF, Landau DA. Cancer evolution: no room for negative selection[J]. Cell, 2017,171(5):987-989. DOI: 10.1016/j.cell.2017.10.039. doi: 10.1016/j.cell.2017.10.039 pmid: 29149612
[5]	Turajlic S, Sottoriva A, Graham T, et al. Resolving genetic heterogeneity in cancer[J]. Nat Rev Genet, 2019,20(7):404-416. DOI: 10.1038/s41576-019-0114-6. doi: 10.1038/s41576-019-0114-6 pmid: 30918367
[6]	Ujvari B, Papenfuss AT, Belov K. Transmissible cancers in an evolutionary context[J]. Bioessays, 2016,38(Suppl 1):S14-S23. DOI: 10.1002/bies.201670904. doi: 10.1002/bies.201670904
[7]	Cannataro VL, Townsend JP. Neutral theory and the somatic evolution of cancer[J]. Mol Biol Evol, 2018,35(6):1308-1315. DOI: 10.1093/molbev/msy079. doi: 10.1093/molbev/msy079 pmid: 29684198
[8]	Persi E, Wolf YI, Leiserson MDM, et al. Criticality in tumor evolution and clinical outcome[J]. Proc Natl Acad Sci U S A, 2018,115(47):E11101-E11110. DOI: 10.1073/pnas.1807256115. doi: 10.1073/pnas.1807256115 pmid: 30404913
[9]	Shaked Y. The pro-tumorigenic host response to cancer therapies[J]. Nat Rev Cancer, 2019,19(12):667-685. DOI: 10.1038/s41568-019-0209-6. doi: 10.1038/s41568-019-0209-6 pmid: 31645711
[10]	Kuczynski EA, Vermeulen PB, Pezzella F, et al. Vessel co-option in cancer[J]. Nat Rev Clin Oncol, 2019,16(8):469-493. DOI: 10.1038/s41571-019-0181-9. doi: 10.1038/s41571-019-0181-9 pmid: 30816337
[11]	Yamamoto TN, Kishton RJ, Restifo NP. Developing neoantigen-targeted T cell-based treatments for solid tumors[J]. Nat Med, 2019,25(10):1488-1499. DOI: 10.1038/s41591-019-0596-y. doi: 10.1038/s41591-019-0596-y pmid: 31591590
[12]	Sanmamed MF, Chen L. A paradigm shift in cancer immunotherapy: from enhancement to normalization[J]. Cell, 2018,175(2):313-326. DOI: 10.1016/j.cell.2018.09.035. doi: 10.1016/j.cell.2018.09.035 pmid: 30290139
[13]	Li X, Wenes M, Romero P, et al. Navigating metabolic pathways to enhance antitumour immunity and immunotherapy[J]. Nat Rev Clin Oncol, 2019,16(7):425-441. DOI: 10.1038/s41571-019-0203-7. doi: 10.1038/s41571-019-0203-7 pmid: 30914826
[14]	Garrett WS. The gut microbiota and colon cancer[J]. Science, 2019,364(6446):1133-1135. DOI: 10.1126/science.aaw2367. doi: 10.1126/science.aaw2367 pmid: 31221845
[15]	Villanueva MT. Cancer: reset your circadian clock[J]. Nat Rev Drug Discov, 2018,17(3):166. DOI: 10.1038/nrd.2018.24. doi: 10.1038/nrd.2018.24 pmid: 29449708
[16]	Madhusoodanan J. News feature: do hosts and their microbes evolve as a unit?[J]. Proc Natl Acad Sci U S A, 2019,116(29):14391-14394. DOI: 10.1073/pnas.1908139116. doi: 10.1073/pnas.1908139116 pmid: 31311888
[17]	Hohenlohe PA, McCallum HI, Jones ME, et al. Conserving adaptive potential: lessons from Tasmanian devils and their transmissible cancer[J]. Conserv Genet, 2019,20(1):81-87. DOI: 10.1007/s10592-019-01157-5. doi: 10.1007/s10592-019-01157-5 pmid: 31551664
[18]	Archetti M, Pienta KJ. Cooperation among cancer cells: applying game theory to cancer[J]. Nat Rev Cancer, 2019,19(2):110-117. DOI: 10.1038/s41568-018-0083-7. doi: 10.1038/s41568-018-0083-7 pmid: 30470829
[19]	Karlsson J, Valind A, Holmquist Mengelbier L, et al. Four evolutionary trajectories underlie genetic intratumoral variation in childhood cancer[J]. Nat Genet, 2018,50(7):944-950. DOI: 10.1038/s41588-018-0131-y. doi: 10.1038/s41588-018-0131-y pmid: 29867221
[20]	Kaznatcheev A, Peacock J, Basanta D, et al. Fibroblasts and alectinib switch the evolutionary games played by non-small cell lung cancer[J]. Nat Ecol Evol, 2019,3(3):450-456. DOI: 10.1038/s41559-018-0768-z. doi: 10.1038/s41559-018-0768-z pmid: 30778184
[21]	Madan E, Pelham CJ, Nagane M, et al. Flower isoforms promote competitive growth in cancer[J]. Nature, 2019,572(7768):260-264. DOI: 10.1038/s41586-019-1429-3. doi: 10.1038/s41586-019-1429-3 pmid: 31341286
[22]	Janiszewska M, Tabassum DP, Castaño Z, et al. Subclonal cooperation drives metastasis by modulating local and systemic immune microenvironments [J]. Nat Cell Biol, 2019,21(7):879-888. DOI: 10.1038/s41556-019-0346-x. doi: 10.1038/s41556-019-0346-x pmid: 31263265
[23]	Tonnessen-Murray CA, Frey WD, Rao SG, et al. Chemotherapy-induced senescent cancer cells engulf other cells to enhance their survival[J]. J Cell Biol, 2019,218(11):3827-3844. DOI: 10.1083/jcb.201904051. doi: 10.1083/jcb.201904051 pmid: 31530580
[24]	Frampton D, Schwenzer H, Marino G, et al. Molecular signatures of regression of the canine transmissible venereal tumor[J]. Cancer Cell, 2018, 33(4):620-633.e6. DOI: 10.1016/j.ccell.2018.03.003. doi: 10.1016/j.ccell.2018.03.003 pmid: 29634949
[25]	Rosenthal R, Cadieux EL, Salgado R, et al. Neoantigen-directed immune escape in lung cancer evolution[J]. Nature, 2019,567(7749):479-485. DOI: 10.1038/s41586-019-1032-7. doi: 10.1038/s41586-019-1032-7 pmid: 30894752
[26]	Angelova M, Mlecnik B, Vasaturo A, et al. Evolution of metastases in space and time under immune selection[J]. Cell, 2018,175(3):751-765.e16. DOI: 10.1016/j.cell.2018.09.018. doi: 10.1016/j.cell.2018.09.018 pmid: 30318143
[27]	Riaz N, Havel JJ, Makarov V, et al. Tumor and microenvironment evolution during immunotherapy with nivolumab[J]. Cell, 2017,171(4):934-949.e16. DOI: 10.1016/j.cell.2017.09.028. doi: 10.1016/j.cell.2017.09.028 pmid: 29033130
[28]	Woolston A, Khan K, Spain G, et al. Genomic and transcriptomic determinants of therapy resistance and immune landscape evolution during anti-EGFR Treatment in colorectal cancer[J]. Cancer Cell, 2019,36(1):35-50.e9. DOI: 10.1016/j.ccell.2019.05.013. doi: 10.1016/j.ccell.2019.05.013 pmid: 31287991
[29]	Boumahdi S, de Sauvage FJ. The great escape: tumour cell plasticity in resistance to targeted therapy[J]. Nat Rev Drug Discov, 2020,19(1):39-56. DOI: 10.1038/s41573-019-0044-1. doi: 10.1038/s41573-019-0044-1 pmid: 31601994
[30]	Demaria O, Cornen S, Daëron M, et al. Harnessing innate immunity in cancer therapy[J]. Nature, 2019,574(7776):45-56. DOI: 10.1038/s41586-019-1593-5. doi: 10.1038/s41586-019-1593-5 pmid: 31578484
[31]	Matyunina EA, Emelyanov AV, Kurbatova TV, et al. Evolutionarily novel genes are expressed in transgenic fish tumors and their orthologs are involved in development of progressive traits in humans[J]. Infect Agent Cancer, 2019,14:46. DOI: 10.1186/s13027-019-0262-5. doi: 10.1186/s13027-019-0262-5 pmid: 31827597
[32]	Makashov AA, Malov SV, Kozlov AP. Oncogenes, tumor suppressor and differentiation genes represent the oldest human geneclasses and evolve concurrently[J]. Sci Rep, 2019,9(1):16410. DOI: 10.1038/s41598-019-52835-w. doi: 10.1038/s41598-019-52835-w pmid: 31712655
[33]	Auslander N, Wolf YI, Koonin EV. In silico learning of tumor evolution through mutational time series[J]. Proc Natl Acad Sci U S A, 2019,116(19):9501-9510. DOI: 10.1073/pnas.1901695116. pmid: 31015295
[34]	Ben-David U, Beroukhim R, Golub TR. Genomic evolution of cancer models: perils and opportunities[J]. Nat Rev Cancer, 2019,19(2):97-109. DOI: 10.1038/s41568-018-0095-3. doi: 10.1038/s41568-018-0095-3 pmid: 30578414
[35]	Montefiori LE, Nobrega MA. Gene therapy for pathologic gene expression[J]. Science, 2019,363(6424):231-232. DOI: 10.1126/science.aaw0635. doi: 10.1126/science.aaw0635 pmid: 30655431
[36]	Porteus MH. A new class of medicines through DNA editing[J]. N Engl J Med, 2019,380(10):947-959. DOI: 10.1056/NEJMra1800729. doi: 10.1056/NEJMra1800729 pmid: 30855744
[37]	Miller AM, Shah RH, Pentsova EI, et al. Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid[J]. Nature, 2019,565(7741):654-658. DOI: 10.1038/s41586-019-0882-3. doi: 10.1038/s41586-019-0882-3 pmid: 30675060
[38]	Hutson M. Bringing machine learning to the masses[J]. Science, 2019,365(6452):416-417. DOI: 10.1126/science.365.6452.416. doi: 10.1126/science.365.6452.416 pmid: 31371586
[39]	Eraslan G Avsec Gagneur J, et al. Deep learning: new computational modelling techniques for genomics[J]. Nat Rev Genet, 2019,20(7):389-403. DOI: 10.1038/s41576-019-0122-6. doi: 10.1038/s41576-019-0122-6 pmid: 30971806